Galapagos to investigate filgotinib in two Phase II trials for Crohn's disease
Belgian clinical-stage biotechnology firm Galapagos is set to investigate filgotinib in two Phase II clinical trials for the treatment of small bowel Crohn's disease and fistulising Crohn's disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | Crohn's Disease | Inflammatory Bowel Disease | Pharmaceuticals